GlobeNewswire·Nov 9, 2026, 4:05 PM ET

Rani Therapeutics Reports Third Quarter 2026 Financial Results; Provides Corporate Update

Rani Therapeutics was accepted into the FDA's Emerging Technology Program in October 2026 to facilitate early engagement on technical, manufacturing & regulatory matters for the RaniPill platform.
Enrollment continues in the RT-114 Phase 1a expansion cohort, with data expected by the end of 2026 to characterize the oral-to-subcutaneous pharmacokinetic relationship.
Cash, cash equivalents & marketable securities totaled $45.3 million as of September 30, 2026, providing funding for operations through at least the end of 2027.
Contract revenue for the third quarter of 2026 was $1.7 million, driven primarily by the collaboration & license agreement with Chugai.
Research & development expenses for the third quarter of 2026 were $6.0 million, an increase from $3.2 million in the same period of 2025.
General & administrative expenses for the third quarter of 2026 were $4.9 million, up from $4.0 million in the same period of 2025.
The net loss for the three months ended September 30, 2026, was $8.8 million, compared to $7.9 million in the same period of 2025.
The company maintains partnerships with Chugai, ProGen & PegBio to advance its oral delivery technology for rare disease, immunology & obesity indications.